UPDATE : Monday, February 17, 2020
상단여백
Eutilex pipelines are underrated: CEO by Jeong Sae-im 2019-08-01 16:08
Biotech industry group urges Japan to withdraw export curbs by Jeong Sae-im 2019-07-25 17:09
[Focus] Korean biopharmas eye US Humira market by Jeong Sae-im 2019-07-25 15:02
Korean drugs strong in anti-reflux treatment market by Jeong Sae-im 2019-07-22 15:15
MedPacto passes tech assessment, seeks KOSDAQ listing this year by Jeong Sae-im 2019-07-19 17:01
라인
Biopharmaceutical stocks face grim outlook in 2H by Jeong Sae-im 2019-07-17 14:11
Korean, Japanese healthcare firms reaffirm ‘joint growth’ amid trade feud by Jeong Sae-im 2019-07-17 14:06
Government faces uphill battle to look into Medytox over illicit drug by Jeong Sae-im 2019-07-15 13:58
Doctors question Pexa-Vec+Imfinzi combo’s effect on colon cancer by Jeong Sae-im, Kim Yun-mi 2019-07-12 15:13
Court suspends decision on ministry’s order to revoke Invossa license by Jeong Sae-im 2019-07-12 13:11
라인
Prosecutors raid 2 lead managers of Kolon TissueGene’s IPO by Jeong Sae-im 2019-07-11 16:39
NKMax America seeks NASDAQ listing by Jeong Sae-im 2019-07-11 12:41
Contera Pharma gets ₩3 billion funding from venture capital by Jeong Sae-im 2019-07-10 17:28
Psomagen seeks KOSDAQ listing using technology exception policy by Jeong Sae-im 2019-07-10 15:20
Court to test Nabota’s spore-forming to end Daewoong-Medytoxin dispute by Jeong Sae-im 2019-07-10 12:44
라인
Kolon files administrative suit against Invossa license revocation by Jeong Sae-im 2019-07-09 11:47
SillaJen shareholders panic over exec’s selling of 160,000 stocks by Jeong Sae-im 2019-07-09 11:45
Kolon TissueGene’s ₩490 billion shares on verge of becoming worthless by Jeong Sae-im 2019-07-08 12:06
Dong-A ST, Dongwha Pharm lose status of innovative drugmaker by Jeong Sae-im 2019-07-05 16:00
Victims question Kolon CEO’s sincerity in apology by Jeong Sae-im 2019-07-05 15:14
여백
여백
여백
Back to Top